NEW YORK, July 18 – Ventana Medical Systems said Wednesday that GlaxoSmithKline has chosen its Discovery in situ hybridization and immunohistochemistry system for use in DNA and protein expression experiments.

GlaxoSmithKline will install six to eight of Ventana’s systems in its European and North American research facilities, Ventana CEO Christopher Gleeson told GenomeWeb. The two companies will also collaborate to develop improvements in tissue gene expression profiling methods.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.